Classic tumor markers in gastric cancer. Current standards and limitations

The progress made in the last few years made available a large amount of information that needs to be integrated and ordered by oncologists. Tumor markers are one of the pieces that physicians need to fit into the bigger puzzle. This article will detail the most frequent etiologies for the surges in...

Descripción completa

Detalles Bibliográficos
Autores principales: CĂINAP, CĂLIN, NAGY, VIORICA, GHERMAN, ALEXANDRA, CETEAN, SANZIANA, LASZLO, ISTVAN, CONSTANTIN, ANNE-MARIE, CĂINAP, SIMONA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iuliu Hatieganu University of Medicine and Pharmacy 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576775/
https://www.ncbi.nlm.nih.gov/pubmed/26528057
http://dx.doi.org/10.15386/cjmed-409
Descripción
Sumario:The progress made in the last few years made available a large amount of information that needs to be integrated and ordered by oncologists. Tumor markers are one of the pieces that physicians need to fit into the bigger puzzle. This article will detail the most frequent etiologies for the surges in the carcinoembryonic antigen (CEA), cancer-related antigen 72-4 (CA 72-4), cancer-related antigen 19-9 (CA 19-9) serum levels and their indications. Although tumor markers are an invaluable asset to medical practice, their role in screening, diagnosis and oncologic treatment remains poorly standardized. Ongoing or future clinical trials will shed light on pending problems.

Ejemplares similares